PDS Biotechnology Corporation (PDSB)

3.3500 -0.0400 (-1.18%) At close: 04:00PM EDT

PDS Biotechnology Corporation

303A College Road East
Princeton, NJ 08540
United States
800 208 3343
https://www.pdsbiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 25

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Frank K. Bedu-Addo Ph.D.	President, CEO & Director	854.1k	N/A	1965
Mr. Lars Robert Boesgaard M.B.A.	Principal Financial & Accounting Officer and CFO	N/A	N/A	1970
Dr. Joe J. Dervan	VP of Research & Development	N/A	N/A	N/A
Dr. Gregory L. Conn Ph.D.	Chief Scientific Officer	220.46k	N/A	1955
Ms. Deanne Randolph	Head of Investor Relations	N/A	N/A	N/A
Mr. Spencer Brown J.D.	Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer	N/A	N/A	1970
Dr. Kirk V. Shepard M.D.	Chief Medical Officer	N/A	N/A	1952
Ms. Janetta Trochimiuk	Controller	N/A	N/A	1963

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Corporate governance

PDS Biotechnology Corporation’s ISS governance QualityScore as of 29 April 2024 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.